The life sciences industry is delivering unprecedented scientific breakthroughs, but bringing those innovations to market is more complex than ever. The opportunity is significant, as blockbuster launches continue to demonstrate the value these therapies can deliver to patients and businesses. Yet more than half of new drugs fail to achieve their first-year revenue targets.
Today’s product launches span more markets, involve more stakeholders, and face greater pricing and access scrutiny than ever before. As launch complexity increases, even small execution gaps can delay patient access, weaken pricing integrity, and materially impact pharma revenue across global markets. For many organizations, the challenge is not just getting the right strategy – it’s execution.
The Problem: More Complexity, Less Room for Error
Modern launches are no longer linear events. They are extended, cross-functional programs that require tight coordination across global and local teams.
Market access organizations must navigate evolving policy and reimbursement environments, new pricing models, increasing international reference pricing exposure, growing executive scrutiny, and the pressure to accelerate time to peak revenue. At the same time, decision-making timelines continue to shrink.
Despite this reality, many organizations still rely on antiquated tools such as spreadsheets, slide decks, and email-driven workflows to manage launch planning. The issue is not complexity itself, but fragmented processes that limit visibility to key data, slow decision-making, and increase risk.
The Impact: When Fragmentation Undermines Execution
When global and local teams lack a shared, real-time view, small changes can create outsized consequences.
Without alignment and shared visibility, teams struggle to maintain an effective global pricing strategy for multi‑country launches. Pricing and timing decisions in a single country ripple across reference markets, altering revenue assumptions well beyond the original market and leaving teams reacting to decisions after execution is already underway.
This is how market access unintentionally becomes a bottleneck, despite years of investment in innovation. And when execution slows, patient access slows as well.
As launch complexity continues to grow, many life sciences teams are reassessing how they plan, coordinate, and execute globally. For additional perspective on how organizations are addressing these challenges, this on‑demand webinar from Model N and CCX explores the connection between launch strategy, market access planning, and revenue execution across global and local teams.
The Solution: Connecting Strategy to Execution
Leading organizations are modernizing how they approach launches by aligning strategy, planning, and execution into a connected process and a consolidated system for both strategy evaluation and contract and price execution.
This approach emphasizes clear global guardrails paired with local flexibility, real‑time collaboration between headquarters and affiliates, and disciplined global price management to continuously evaluate scenarios as conditions change. Crucially, approved strategies flow directly into execution, ensuring pricing decisions and governance remain intact throughout the launch lifecycle.
When strategy and execution are truly connected, teams can adapt quickly without losing control. Decisions are made with confidence because their enterprise‑wide impact is visible before they are finalized.
Why This Matters Now
Launch complexity is not a temporary challenge. Pricing pressure, policy change, and global coordination requirements will continue to intensify.
Organizations that succeed will be those that move beyond fragmented planning models and manual execution workflows. By modernizing how launches are planned and executed, life sciences teams can reduce risk, accelerate access, and improve predictability at one of the most critical moments in the product lifecycle.
Contact us to learn how Model N can support your team with complex product launches.
